DMD03
MUNIi003-A
General
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 15-19 |
Ethnicity | caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Family history | no related to case |
Is the medical history available upon request? | rapid progression, mild cardiac phenotype |
Is clinical information available? | early onset of cardiac phenotype |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
|
External Databases (Donor) |
|
BioSamples | SAMEA5573704 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | No |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | Yes |
Details on restriction to research project | |
Does consent permit unforeseen future research, without further consent? | No |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | Yes |
Does consent expressly permit collection of genetic information? | Yes |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | Yes |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Does consent permit access to medical records of the donor? | Yes |
Please describe how access is provided: | |
Does consent permit access to any other source of information about the clinical treatment or health of the donor? | Yes |
Contact data, institution, or website: | Masaryk University, Pediatric Neurology Clinic |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Ethics Committee, Medical faculty, Masaryk University |
Approval number | 13/2012 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Ethics Committee, Medical faculty, Masaryk University |
Approval number | 13/2012 |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
Is there an MTA available for the cell line? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Life Technologies |
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
Source cell type |
Synonyms
|
Source cell origin |
A zone of skin that is part of a leg [Automatically generated definition].
Synonyms
|
Age of donor (at collection) | 15-19 |
Collected in | 2013 |
Passage number reprogrammed | 3 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
Selection criteria for clones | morphology, alcaline phophatase, SSEA, Oct4, Nanog |
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Gelatin | ||||||||||||
Feeder cells |
mouse embryonic fibroblast Cellfinder Ont Id: EFO_0004040 |
||||||||||||
Passage method | Mechanically | ||||||||||||
O2 Concentration | 20 % | ||||||||||||
CO2 Concentration | 5 % | ||||||||||||
Medium |
Other medium:
Base medium: Dulbecco`s modified Eagle medium (DMEM)/F12
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
Alkaline Phosphatase |
Yes |
|
||||
NANOG |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-3 |
Yes |
|
||||
TRA 1-81 |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
In vitro directed differentiation
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.